Pancreatic neuroendocrine tumor
MONDO:0019954Pancreatic endocrine tumor, also known as pancreatic neuroendocrine tumor (PNET), describes a group of endocrine tumors originating in the pancreas that are usually indolent and benign, but may have the potential to be malignant. They can be functional, exhibiting a hormonal hypersecretion syndrome, but can be non-functional presenting with non-specific symptoms and include insulinoma, glucagonoma, VIPoma, somatostatinoma (SSoma), PPoma and Zollinger-Ellison syndrome (ZES, or gastrinoma) and other ectopic hormone producing tumors (such as GRFoma).
Also known as: islet cell tumor, islet cell tumors - pancreas, islet cell tumors of the pancreas, islet cell tumour, islet cell tumours - pancreas, islet cell tumours of the pancreas, pancreatic NET, pancreatic neuroendocrine tumor
1556 clinical trials for this condition and its sub-types, 60 tagged with Pancreatic neuroendocrine tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pancreatic neuroendocrine tumor
-
Functional pancreatic neuroendocrine tumor 1 trial · 14 incl. sub-types
3 sub-types
- Pancreatic insulinoma 13 trials
- Pancreatic ACTH-producing neuroendocrine tumor 0 trials
- Pancreatic gastrinoma 0 trials
-
Pancreatic insulin-producing neuroendocrine tumor 0 trials · 13 incl. sub-types
1 sub-type
- Pancreatic insulinoma 13 trials
-
Somatostatinoma 6 trials
-
Pancreatic neuroendocrine tumor G1 1 trial · 5 incl. sub-types
1 sub-type
-
1 sub-type
-
Glucagonoma 2 trials
-
1 sub-type
- Pancreatic gastrinoma 0 trials
-
PPoma 1 trial
-
VIPoma 1 trial
2 sub-types
-
GRFoma 0 trials
-
2 sub-types
- Pancreatic non-functioning delta cell tumor 0 trials
- Pancreatic somatostatinoma 0 trials
-
Can a new drug formulation shrink Hard-to-Treat neuroendocrine tumors?
Disease control CompletedThis phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New vaccine aims to train immune system to fight neuroendocrine tumors
Disease control CompletedThis early-phase trial tested a vaccine called SurVaxM in 19 people with metastatic neuroendocrine tumors. The vaccine is designed to teach the immune system to recognize and attack tumor cells that produce a protein called survivin. The main goal was to see if the vaccine is saf…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Robot surgeons take on pancreatic cancer in major trial
Disease control CompletedThis study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New scan lights up hidden gut tumors
Diagnosis CompletedThis completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accuratel…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Can acupuncture and ice chips beat chemo nerve damage?
Symptom relief CompletedThis phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …
Phase 2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New risk score aims to predict which pancreatic tumors will return after surgery
Knowledge-focused CompletedThis study aims to create a simple risk score to identify patients with pancreatic neuroendocrine tumors (PanNETs) who are at high risk of their cancer returning after surgery. Current methods are not very good at predicting individual risk. Researchers will analyze data from ove…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC